PT773957E - Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos - Google Patents

Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos

Info

Publication number
PT773957E
PT773957E PT95928779T PT95928779T PT773957E PT 773957 E PT773957 E PT 773957E PT 95928779 T PT95928779 T PT 95928779T PT 95928779 T PT95928779 T PT 95928779T PT 773957 E PT773957 E PT 773957E
Authority
PT
Portugal
Prior art keywords
hepatitis
innovative
polypeptides
methods
themselves
Prior art date
Application number
PT95928779T
Other languages
English (en)
Inventor
Michael Houghton
Mark Selby
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of PT773957E publication Critical patent/PT773957E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT95928779T 1994-07-29 1995-07-26 Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos PT773957E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28295994A 1994-07-29 1994-07-29

Publications (1)

Publication Number Publication Date
PT773957E true PT773957E (pt) 2005-11-30

Family

ID=23083871

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95928779T PT773957E (pt) 1994-07-29 1995-07-26 Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos

Country Status (5)

Country Link
US (1) US6121020A (pt)
AU (1) AU3241095A (pt)
PT (1) PT773957E (pt)
WO (1) WO1996004301A2 (pt)
ZA (1) ZA956318B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0721505T4 (da) * 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
WO1996041196A1 (en) * 1995-06-07 1996-12-19 Abbott Laboratories Method for detection of antibody to hepatitis c virus second envelope glycoprotein
KR970065716A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(한국형)의 분비형 외피단백질 1 및 2
KR970065713A (ko) * 1996-03-19 1997-10-13 성재갑 C형 간염 바이러스(일본형)의 분비형 외피 단백질 1 및 2
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
AU738585B2 (en) 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
EP0980434B1 (en) * 1997-05-06 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Intracellular production of hepatitis c e2 truncated polypeptid
WO1999066033A1 (en) * 1998-06-18 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtha Nd Human Services Surface targeted expression of a modified hepatitis c virus envelope protein
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US6995299B2 (en) * 1999-11-02 2006-02-07 University Of Connecticut Propagation of human hepatocytes in non-human animals
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
ATE413190T1 (de) * 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
US6682909B2 (en) 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof
AU2001216030A1 (en) * 2000-11-14 2002-05-27 Morphotek Inc. A method for generating genetically altered antigens
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
EP1572124A4 (en) * 2001-06-29 2007-11-28 Novartis Vaccines & Diagnostic HCV E1E2 VACCINE COMPOSITIONS
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP1497469A4 (en) * 2002-04-04 2005-06-08 Achillion Pharmaceuticals Inc TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC
WO2004037847A2 (en) 2002-05-07 2004-05-06 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
US20060088819A1 (en) * 2004-05-17 2006-04-27 Chiron Corporation Truncated hepatitis C virus NS5 domain and fusion proteins comprising same
EP1784513A4 (en) 2004-06-08 2010-01-06 Novartis Vaccines & Diagnostic FUSION PROTEINS COMPRISING MINIMUM CD4 MODULES AND METHODS OF USING SAME
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006084179A2 (en) 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics Inc. Hiv tat-cd4 hybried molecules and methods of use thereof
AU2007291936B2 (en) * 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
US10080799B2 (en) * 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
AU2014385320B2 (en) 2013-05-15 2019-10-10 The Governors Of The University Of Alberta E1E2 HCV vaccines and methods of use
EP3319997A4 (en) 2015-07-07 2019-01-23 The Governors of the University of Alberta IMMUNOGENIC COMPOSITIONS BASED ON HEPATITIS C VIRUS AND METHODS OF USE
EP3525817A4 (en) 2016-10-11 2020-09-16 The Governors of the University of Alberta IMMUNOGENIC HEPATITIS C VIRUS COMPOSITIONS WITH A CYCLIC DINUCLEOTIDE OR ARCHAEOSOME AS ADJUVANS AND METHOD OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049686C (zh) * 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
GEP20002164B (en) * 1989-05-18 2000-07-10 Novartis Vaccines & Diagnostic Oligomers, method for detecting of hcv sequence, kit for its detecting, method for production of the blood free from hcv
CA2088599A1 (en) * 1990-08-02 1992-02-03 Carol A. Pachl Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
RO115446B1 (ro) * 1990-11-08 2000-02-28 Chiron Corp Procedeu de obtinere a asialoglicoproteinelor purificate provenind de la virusul hepatitei c

Also Published As

Publication number Publication date
AU3241095A (en) 1996-03-04
WO1996004301A3 (en) 1996-03-28
ZA956318B (en) 1996-03-07
US6121020A (en) 2000-09-19
WO1996004301A2 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
PT773957E (pt) Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
FI950249A (fi) Sähkökirurgisia kärkiä ja menetelmiä
NO20004104D0 (no) Preparater omfattende virus og fremgangsmÕter for konsentrering av viruspreparater
DE69814069D1 (de) Neuartige form von s-omeprazol
DE69725205D1 (de) Befestigung von Biomolekülen
DE69718393D1 (de) Befestigung von Biomolekülen
PT946323E (pt) Pos de niobio e condensadores eletroliticos de niobio
ID17767A (id) Vaksin dan polipeptida-polipeptida sampul hiv
ID24476A (id) Arilsulfonamida dan analognya
BR9710067A (pt) Arroz de cozimento rápido e instântaneo e processos de obtenção dos mesmos
NO964006L (no) Fremgangsmåte for kontinuerlig koking av vörter
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
AU1905399A (en) Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
IT8922605A0 (it) Tenuta di ugello di scarico assialmente simmetrico e direzionale
EP0747482A3 (en) Recombinant hepatitis GB virus proteins their uses
DK0826679T3 (da) Naphthylforbindelser og -præparater
ATE100441T1 (de) Substituierte glutaramidsaeuren und derivate.
FR11C0050I2 (fr) Virus myxomateux recombinant
PT96225A (pt) Aquecedor de chumaceiras e similares
FI935654A0 (fi) Kondenserade heterocykliska foereningar, deras framstaellning och anvaendning
FR2753970B1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
FI955537A0 (fi) Fibrinolyyttiset ja hyytymistä estävät proteiinit
BR9611895A (pt) Derivados de 5-naftalen-1,3-dioxano preparação e uso terapêutico dos mesmos
DE19681235D2 (de) Verfahren zur Deaktivierung der HIV und anderer Viren
FI943929A0 (fi) Hepatiitti C-viruspeptidejä